Study Links Fructose to Ovarian Cancer Metastasis Following Chemotherapy
In 2026, an estimated 21,010 new cases of ovarian cancer are expected to be diagnosed in the United States, a type of cancer that has a 52% relative five-year survival rate. Despite chemotherapy being a common treatment, it does not always eliminate cancer cells, leading to metastasis, or the spread of cancer throughout the body. Researchers from The Wistar Institute at the University of Pennsylvania have investigated the mechanisms behind this phenomenon, focusing on how ovarian cancer cells can proliferate after surviving chemotherapy. Katherine Aird, PhD, a senior author of the study published in Nature Aging, emphasized that while chemotherapy is effective, some cancer cells can endure treatment and subsequently release factors that promote cancer progression. The study identifies fructose as a surprising contributor to this process. Ovarian cancer often presents with vague symptoms, making early diagnosis challenging. By the time it is detected, it is frequently at an advanced stage. The researchers found that chemotherapy induces a state called cellular senescence in cancer cells, where they cease to divide but remain metabolically active. This raises the question of how these non-dividing cells can still facilitate cancer spread. Past research suggests that senescent cancer cells can secrete signaling molecules that influence neighboring cells, promoting their proliferation. In this study, the team collected ovarian cancer cells exposed to chemotherapy and analyzed the signaling molecules they released. They discovered that these molecules, particularly fructose, enhance the ability of other cancer cells to spread. Aird noted that fructose, commonly found in fruits and high-fructose corn syrup, is processed by cancer cells in a manner that reduces cholesterol production, which is crucial for maintaining cell adhesion. The absence of cholesterol allows cancer cells to detach and spread more easily. Furthermore, the researchers observed that a diet high in fructose could exacerbate cancer spread, although the exact impact of dietary choices on ovarian cancer metastasis remains to be fully established. Aird cautioned that these findings are based on preclinical research and require further validation in human studies. She highlighted the need to understand the negative consequences of chemotherapy better and the potential implications of a high-fructose diet on cancer outcomes. Experts like Nathan Goodyear, MD, emphasized that this study reframes the understanding of fructose in cancer biology, suggesting it plays a pivotal role in the relationship between chemotherapy and metastasis. The findings open new avenues for research, including potential dietary interventions and drugs targeting the fructose-cholesterol pathway. However, Vaidya, another expert, reminded that while the study presents significant insights, it is essential to continue relying on established treatment protocols and to consider lifestyle factors that may influence cancer risk. The ongoing research aims to explore how dietary intake correlates with patient outcomes and to identify other nutrients released by chemotherapy-surviving cells that could inform future cancer therapies.




